Drug Profile
Research programme: rheumatoid arthritis therapeutics - 4SC
Latest Information Update: 11 Oct 2013
Price :
$50
*
At a glance
- Originator 4SC
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 10 Oct 2013 Discontinued for Rheumatoid arthritis in Germany (unspecified route)
- 10 Jan 2011 Consortium including 4SC receives grant from the European Union for drug development in Rheumatoid arthritis
- 10 Jan 2011 Early research in Rheumatoid arthritis in Germany (unspecified route)